Depressive symptoms, neurocognitive impairment, and adherence to highly active antiretroviral therapy among HIV-infected persons

Psychosomatics

Volumn 45, Issue 5, 2004, Pages 394-402

  Ammassari, Adriana ^a   Antinori, Andrea ^b   Aloisi, Maria Stella ^b   Trotta, Maria Paola ^b   Murri, Rita ^b   Bartoli, Luca ^b   D'Arminio Monforte, Antonella ^b   Wu, Albert W ^b   Starace, Fabrizio ^b  

^a CATHOLIC UNIVERSITY   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ARTICLE; COGNITIVE DEFECT; DEPRESSION; DISEASE ASSOCIATION; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; NEUROPSYCHOLOGICAL TEST; PATIENT COMPLIANCE; RATING SCALE; SEXUAL BEHAVIOR;

EID: 4444291864     PISSN: 00333182     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.psy.45.5.394     Document Type: Article

References (39)

1. Rodriguez-Rosado R, Jimenez-Nacher I, Soriano V, Anton P, Gonzalez-Lahoz J: Virological failure and adherence to antiretroviral therapy in HIV-infected patients. AIDS 1998; 12:1112-1113
2. Haubrich RH, Little SJ, Currier JS, Forthal DN, Kemper CA, Beall GN, Johnson D, Dube MP, Hwang JY, McCutchan JA: The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response. AIDS 1999; 13:1099-1107
3. Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, Wagener MM, Singh N: Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000; 133:21-30
4. Bangsberg DR, Hecht FM, Charlebois ED, Zolopa AR, Holodniy M, Sheiner L, Bamberger JD, Chesney MA, Moss A: Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS 2000; 14:357-366
5. Gordillo V, del Amo J, Soriano V, Gonzalez-Lahoz J: Sociodemographic and psychological variables influencing adherence to antiretroviral therapy. AIDS 1999; 13:1763-1769
6. Gifford AL, Bormann JE, Shively MJ, Wright BC, Richman DD, Bozzette SA: Predictors of self-reported adherence and plasma HIV concentrations in patients on multidrug antiretroviral regimens. J Acquir Immune Defic Syndr 2000; 23:386-395
7. Bing EG, Burnam MA, Longshore D, Fleishman JA, Sherboume CD, London AS, Turner BJ, Eggan F, Beckman R, Vitiello B, Morton SC, Orlando M, Bozzette SA, Ortiz-Barron L, Shapiro M: Psychiatric disorders and drug use among human immunodeficiency virus-infected adults in the United States. Arch Gen Psychiatry 2001; 58:721-728
8. Low-Beer S, Chan K, Yip B, Wood E, Montaner JS, O'Shaughnessy MV, Hogg RS: Depressive symptoms decline among persons on HIV protease inhibitors. J Acquir Immune Defic Syndr 2000; 23:295-301
9. von Giesen HJ, Hefter H, Jablonowski H, Arendt G: HAART is neuroprophylactic in HIV-1 infection. J Acquir Immune Defic Syndr 2000; 23:380-385
10. Sacktor N, Lyles RH, Skolasky R, Kleeberger C, Selnes OA, Miller EN, Becker JT, Cohen B, McArthur JC: HIV-associated neurologic disease incidence changes: Multicenter AIDS Cohort Study, 1990-1998. Neurology 2001; 56:257-260
11. Ferrando S, van Gorp W, McElhiney M, Goggin K, Sewell M, Rabkin J: Highly active antiretroviral treatment in HIV infection: benefits for neuropsychological function. AIDS 1998; 12:65-70
12. Tozzi V, Balestra P, Galgani S, Narciso P, Ferri F, Sebastiani G, D'Amato C, Affricano C, Pigorini F, Pau FM, De Felici A, Benedetto A: Positive and sustained effects of highly active antiretroviral therapy on HIV-1-associated neurocognitive impairment. AIDS 1999; 13:1889-1897
13. Dore GJ, Correll PK, Li Y, Kaldor JM, Cooper DA, Brew BJ: Changes to AIDS dementia complex in the era of highly active antiretroviral therapy. AIDS 1999; 13:1249-1253
14. Antinori A, Ammassari A, Cinque P, et al: Shift of prevalence and selected characteristics in HIV-1-related neurologic disorders in HAART era: data from Italian Register Investigative NeuroAIDS (IRINA), in Program and Abstracts of the 8th Conference on Retroviruses and Opportunistic Infections. Alexandria, VA, Foundation for Retrovirology and Human Health, 2001
15. Holzemer WL, Corless IB, Nokes KM, Turner JG, Brown MA, Powell-Cope GM, Inouye J, Henry SB, Nicholas PK, Portillo CJ: Predictors of self-reported adherence in persons living with HIV disease. AIDS Pat Care STDS 1999; 13:185-197
16. Catz SL, Kelly JA, Bogart LM, Benotsch EG, McAuliffe TL: Patterns, correlates, and barriers to medication adherence among persons prescribed new treatments for HIV disease. Health Psychol 2000; 19:124-133
17. DiMatteo MR, Lepper HS, Croghan TW: Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effect of anxiety and depression on patient adherence. Arch Intern Med 2000; 160:2101-2107
18. Hinkin CH, Castellon SA, Durvasula RS, Hardy DJ, Lam MN, Mason KI, Thrasher D, Goetz MB, Stefaniak M: Medication adherence among HIV + adults: effects of cognitive dysfunction and regimen complexity. Neurology 2002; 59:1944-1950
19. d'Arminio Monforte A, Lepri AC, Rezza G, Pezzotti P, Antinori A, Phillips AN, Angarano G, Colangeli V, De Luca A, Ippolito G, Caggese L, Soscia F, Filice G, Gritti F, Narciso P, Tirelli U, Moroni M: Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in cohort of antiretroviral-naive patients. ICONA Study Group Italian Cohort of Antiretroviral Naive Patients. AIDS 2000; 14:499-507
20. Ammassari A, Murri R, Pezzotti P, Trotta MP, Ravasio L, De Longis P, Lo Caputo S, Narciso P, Pauluzzi S, Carosi G, Nappa S, Piano P, Izzo CM, Lichtner M, Rezza G, Monforte A, Ippolito G, d'Arminio Moroni M, Wu AW, Antinori A, AdICONA Study Group: Self-reported symptoms and medication side effects influence adherence to HAART in persons with HIV infection. J Acquir Immune Defic Syndr 2001; 28:445-449
21. Starace F, Bartoli L, Aloisi MS, Antinori A, Narciso P, Ippolito G, Ravasio L, Moioli MC, Vangi D, Gennero L, Coronado OV, Giacometti A, Nappa S, Perulli ML, Montesarchio V, La Gala A, Ricci F, Cristiano L, De Marco M, Izzo C, Pezzotti P, D'Arminio Monforte A: Cognitive and affective disorders associated to HIV infection in the HAART era: findings from the NeuroICONA study. Cognitive impairment and depression in HIV/AIDS. The NeuroICONA study. Acta Psychiatr Scand 2002; 106:20-26
22. Sidtis JJ, Price RW: Early HIV-1 infection and the AIDS dementia complex. Neurology 1990; 40:323-326
23. Murri R, Ammassari A, Gallicano K, De Luca A, Cingolani A, Jacobson D, Wu AW, Antinori A: Patient-reported nonadherence to HAART is related to protease inhibitor levels. J Acquir Immune Defic Syndr 2000; 24:123-128
24. Whalen CC, Antani M, Carey J, Landefield CS: An index of symptoms for infection with human immunodeficiency virus: reliability and validity. J Clin Epidemiol 1994; 47:537-546
25. Max B, Sherer R: Management of the adverse effects of antiretroviral therapy and medication adherence. Clin Infect Dis 2000; 30:S96-S116
26. Wu AW, Rubin HR, Mathews WC, Ware JE Jr, Brysk LT, Hardy WD, Bozzette SA, Spector SA, Richman DD: A health status questionnaire using 30 items from the Medical Outcomes Study: preliminary validation in persons with early HIV infection. Med Care 1991; 29:786-798
27. Montgomery S, Åsberg M: A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134:382-389
28. Maj M, Starace F, Sartorius N: Neuropsychiatric aspects of HIV-1 infection: data collection instrument for a WHO cross-cultural study. Bull World Health Organ 1991; 69:241-245
29. Wechsler D, Green RF, Martinez JN: Manual para la escala de inteligencia Wechsler para adultos. Cleveland, Psychological Corp, 1968
30. Starace F, Baldassarre C, Biancolilli V, Fea M, Serpelloni G, Bartoli L, Maj M: Early neuropsychological impairment in HIV-seropositive intravenous drug users: evidence from the Italian Multicentre Neuropsychological HIV Study. Acta Psychiatr Scand 1998; 97:132-138
31. Ickovics JR, Hamburger ME, Vlahov D, Schoenbaum EE, Schuman P, Boland RJ, Moore J; HIV Epidemiology Research Study Group: Mortality, CD4 cell count decline, and depressive symptoms among HIV-seropositive women. JAMA 2001; 285:1466-1474
32. Rabkin JG, Ferrando SJ, Jacobsberg LB, Fishman B: Prevalence of axis I disorders in an AIDS cohort: a cross-sectional, controlled study. Compr Psychiatry 1997; 38:146-154
33. Eldred LJ, Wu AW, Chaisson RE, Moore RD: Adherence to antiretroviral and Pneumocystis prophylaxis in HIV disease. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 18:117-125
34. Duran S, Spire B, Raffi F, Walter V, Bouhour D, Journot V, Cailleton V, Leport C, Moatti JP; APROCO Cohort Study Group: Self-reported symptoms after initiation of protease inhibitor in HIV-infected patients and their impact on adherence to HAART. HIV Clin Trials 2001; 2:38-45
35. Jones M, Klimes I, Catalan J: Psychosexual problems in people with HIV infection: controlled study of gay men and men with haemophilia. AIDS Care; 5:587-593
36. Martinez E, Collazos J, Mayo J, Blanco MS: Sexual dysfunction with protease inhibitors. Lancet 1999; 353:810-811
37. Schrooten W, Colebunders R, Youle M, Molenberghs G, Dedes N, Koitz G, Finazzi R, de Mey I, Florence E, Dreezen C; Eurosupport Study Group: Sexual dysfunction associated with protease inhibitor containing highly active antiretroviral treatment. AIDS 2001; 15:1019-1023
38. Moatti JP, Carrieri MP, Spire B, Gastaut JA, Cassuto JP, Moreau J: Adherence to HAART in French HIV-infected injecting drug users: the contribution of buprenorphine drug maintenance treatment. AIDS 2000; 14:151-155
39. Trotta MP, Ammassari A, Cozzi-Lepri A, Zaccarelli M, Castelli F, Narciso P, Melzi S, De Luca A, Monforte AD, Antinori A; Adherence Italian Cohort Naive Antiretrovirals (AdICONA) Study Group; Adherence Spallanzani (AdeSpall) Study Group: Adherence to highly active antiretroviral therapy is better in patients receiving non-nucleoside reverse transcriptase inhibitor-containing regimens than in those receiving protease inhibitor-containing regimens. AIDS 2003; 17:1099-1102